Palmer SC, Mavridis D, Johnson DW, et al. - Researchers analyzed the published data to compare the effectiveness of 3 calcimimetic agents (etelcalcetide, evocalcet and cinacalcet) for the treatment of secondary hyperparathyroidism, via a systematic review of randomized controlled trials and network meta-analysis. They analyzed adults suffering from chronic kidney disease enrolled in a clinical trial of a calcimetic agent. They explored MEDLINE, EMBASE, CENTRAL (from February 7, 2013, to November 21, 2019) to identify relevant data. Overall 36 trials with 11,247 participants were analyzed, and all except 4 trials included dialysis patients. Higher odds of attaining target parathyroid hormone (PTH) levels, with high or moderate certainty, was reported for calcimimetic agents vs placebo. The highest odds of achieving a PTH target were reported for etelcalcetide vs evocalcet and cinacalcet. Experts noted that evidence of the advantages of calcimimetic therapy was limited to short-term evaluation of a putative surrogate outcome (serum PTH). Although the largest decline in PTH levels was observed with etelcalcetide, but still 1 preferred agent could not be identified because the observed side-effect profiles varied across the 3 calcimimetic agents.